Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sudhir Agrawal
AddedMar 31, 2024
UpdatedMay 31, 2026
Sudhir Agrawal

Sudhir Agrawal

Board Member, Quiver Bioscience

WebsiteCrunchbaseLinkedIn

Sudhir Agrawal's Career

Quiver Bioscience
Quiver Bioscience

Cambridge, MA, US

Board Member· Board
Envisagenics
Envisagenics

New York City, NY, US

Board Member· Board
QurAlis
QurAlis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sudhir Agrawal's Career

Quiver Bioscience
Quiver Bioscience
Pre-Seed$22.5M292013Cambridge, MA, US
Board Member· Board

Recent news

Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q SyndromeBioSpace · 2026
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic EpilepsiesBusiness Wire · 2026
Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug SafetyBusiness Wire · 2025

Leadership at Quiver Bioscience

Aayush ShroffAayush ShroffResearch Associate III
Adam CohenAdam CohenScientific Advisory Board Member
Aishwarya DhandapaniAishwarya DhandapaniAssociate Scientist
Alan KopinAlan KopinScientific Advisory Board Member
Amy ElderAmy ElderConsulting Director of Chemistry
Anne CarpenterAnne CarpenterScientific Advisory Board Member

Similar to Quiver Bioscience

Verge GenomicsVerge GenomicsSan Francisco, CA, USDrug Developmentest. 2015Verge GenomicsSan Francisco, CA, US · est. 2015

Verge Genomics accelerates drug development for neuro diseases using AI and human data.

Series B · $134.1M83
Quadrant BiosciencesQuadrant BiosciencesSyracuse, NY, USDiagnostics, Healthcareest. 2015Quadrant BiosciencesSyracuse, NY, US · est. 2015

Quadrant Biosciences develops and distributes innovative epigenetic diagnostics for early detection of neurological disorders.

Seed · $10M81
Curi BioCuri BioSeattle, WA, USBiotech, Drug Discoveryest. 2015Curi BioSeattle, WA, US · est. 2015

Curi Bio: Accelerating next-gen medicine discovery through human cells, systems, and data integration.

Series A · $20.4M45
System1 BiosciencesSystem1 BiosciencesSan Francisco, CA, USDrugs, Neurotherapeuticsest. 2017System1 BiosciencesSan Francisco, CA, US · est. 2017

System1 Biosciences, a neurotherapeutics firm, uses advanced tech to discover drugs for complex neurological disorders.

Series A · $25M30
Envisagenics
Envisagenics
Series A$27.1M472014New York City, NY, US
Board Member· Board

Leadership at Envisagenics

Martin AkermanMartin AkermanCo-Founder
Maria Luisa PinedaMaria Luisa PinedaCo-Founder
Grant VerstandigGrant VerstandigBoard Member

Similar to Envisagenics

Enveda BiosciencesEnveda BiosciencesBoulder, CO, USDrug Discoveryest. 2019Enveda BiosciencesBoulder, CO, US · est. 2019

Enveda Biosciences, a Boulder-based biotech firm, innovatively transforms plant molecules into drugs using advanced AI.

Series B · $174.9M175
SrnalyticsSrnalyticsWaltham, MA, USDrug Discoveryest. 2016SrnalyticsWaltham, MA, US · est. 2016

sRNAlytics: Pioneering small RNA research with technology and services for accelerated drug discovery.

Seed · $2.5M9
Atomic AIAtomic AISouth San Francisco, CA, USDrug Discoveryest. 2021Atomic AISouth San Francisco, CA, US · est. 2021

Atomic AI: Pioneering molecule and medicine design through AI and structural biology fusion.

Series A · $42M38
OwkinOwkinNew York City, NY, USAI Drug Discovery, Diagnosticsest. 2016OwkinNew York City, NY, US · est. 2016

NYC-based Owkin, Inc. leverages machine learning for predictive analytics in biotech, serving global pharma.

Series B · $304.1M441
QurAlis
QurAlis
Series B$135.5M582016Cambridge, MA, US
Board Member· Board

Leadership at QurAlis

Anne WhitakerAnne WhitakerBoard Member
Kasper RoetKasper RoetCo-Founder
Clifford WoolfClifford WoolfCo-Founder
Cillian KingCillian KingBoard Member
Laia CrespoLaia CrespoBoard Member
Jeffrey MooreJeffrey MooreBoard Member

People Similar to Sudhir Agrawal

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoBrian KimBrian KimBoard Member · KakaoHong EuntaekHong EuntaekBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · KakaoAlexander KeeslingAlexander KeeslingCEO · QuEra ComputingAndrei GudkovAndrei GudkovCo-Founder · Cleveland BioLabsRichard ScheuermannRichard ScheuermannBoard Member · Human LongevityNicole PaulkNicole PaulkBoard Member · GRO BiosciencesWalter GreenleafWalter GreenleafBoard Member · Joyance PartnersJustin StebbingJustin StebbingBoard Member · NightHawk Biosciences